Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100


Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.

Stanley TL, Falutz J, Marsolais C, Morin J, Soulban G, Mamputu JC, Assaad H, Turner R, Grinspoon SK.

Clin Infect Dis. 2012 Jun;54(11):1642-51. doi: 10.1093/cid/cis251. Epub 2012 Apr 10.


Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Stanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK.

JAMA. 2014 Jul 23-30;312(4):380-9. doi: 10.1001/jama.2014.8334.


Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S.

J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. doi: 10.1210/jc.2010-0490. Epub 2010 Jun 16.


Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction.

Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK.

AIDS. 2011 Jun 19;25(10):1281-8. doi: 10.1097/QAD.0b013e328347f3f1.


Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.

Mangili A, Falutz J, Mamputu JC, Stepanians M, Hayward B.

PLoS One. 2015 Oct 12;10(10):e0140358. doi: 10.1371/journal.pone.0140358. eCollection 2015.


Metabolic effects of a growth hormone-releasing factor in patients with HIV.

Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

N Engl J Med. 2007 Dec 6;357(23):2359-70.


Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S.

AIDS. 2008 Sep 12;22(14):1719-28. doi: 10.1097/QAD.0b013e32830a5058.


Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, Berger D, Somero M, Moyle G, Brown S, Martorell C, Turner R, Grinspoon S.

J Acquir Immune Defic Syndr. 2010 Mar;53(3):311-22. doi: 10.1097/QAI.0b013e3181cbdaff.


Spotlight on tesamorelin in HIV-associated lipodystrophy.

Dhillon S.

BioDrugs. 2011 Dec 1;25(6):405-8. doi: 10.2165/11208290-000000000-00000. Review.


Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Dhillon S.

Drugs. 2011 May 28;71(8):1071-91. doi: 10.2165/11202240-000000000-00000. Review.


Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.

Spooner LM, Olin JL.

Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. Review.


A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

Falutz J, Allas S, Kotler D, Thompson M, Koutkia P, Albu J, Trottier B, Routy JP, Cote P, Abribat T, Grinspoon S.

AIDS. 2005 Aug 12;19(12):1279-87.


Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.

Makimura H, Feldpausch MN, Rope AM, Hemphill LC, Torriani M, Lee H, Grinspoon SK.

J Clin Endocrinol Metab. 2012 Dec;97(12):4769-79. doi: 10.1210/jc.2012-2794. Epub 2012 Sep 26.


Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials.

Sivakumar T, Mechanic O, Fehmie DA, Paul B.

HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111/j.1468-1293.2010.00906.x. Epub 2011 Jan 25. Review.


Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.

Lo J, You SM, Canavan B, Liebau J, Beltrani G, Koutkia P, Hemphill L, Lee H, Grinspoon S.

JAMA. 2008 Aug 6;300(5):509-19. doi: 10.1001/jama.300.5.509.


Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.

Koutkia P, Canavan B, Breu J, Torriani M, Kissko J, Grinspoon S.

JAMA. 2004 Jul 14;292(2):210-8.


Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients.

Jemsek JG, Arathoon E, Arlotti M, Perez C, Sosa N, Pokrovskiy V, Thiry A, Soccodato M, Noor MA, Giordano M.

Clin Infect Dis. 2006 Jan 15;42(2):273-80. Epub 2005 Dec 5.


Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.

McComsey GA, Kitch D, Sax PE, Tebas P, Tierney C, Jahed NC, Myers L, Melbourne K, Ha B, Daar ES.

Clin Infect Dis. 2011 Jul 15;53(2):185-96. doi: 10.1093/cid/cir324.


A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy.

Kohli R, Shevitz A, Gorbach S, Wanke C.

HIV Med. 2007 Oct;8(7):420-6.


Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.

Tebas P, Zhang J, Hafner R, Tashima K, Shevitz A, Yarasheski K, Berzins B, Owens S, Forand J, Evans S, Murphy R.

J Antimicrob Chemother. 2009 May;63(5):998-1005. doi: 10.1093/jac/dkp071. Epub 2009 Mar 19.

Items per page

Supplemental Content

Write to the Help Desk